biotech | Doctors In Business Journal

top of page

The Doctors in Business Journal

BioNTech stock surge June 2 2025, BioNTech ADR rises 18% explanation, BNTX volume spike June 2025, Bristol Myers Squibb BioNTech deal details, how to interpret heavy trading volume in biotech stocks, BioNTech valuation after BMS partnership, biotech M&A and licensing impact on share price, BNTX 52-week high comparison.

BioNTech stock surge June 2 2025, BioNTech ADR rises 18% explanation, BNTX volume spike June 2025, Bristol Myers Squibb BioNTech deal details, how to interpret heavy trading volume in biotech stocks, BioNTech valuation after BMS partnership, biotech M&A and licensing impact on share price, BNTX 52-week high comparison.

BioNTech SE ADR Rises 18%, Outperforms Market

On June 2, 2025 BioNTech SE’s American depositary receipt staged a dramatic one-day rally, closing up 18.0% at $113.10. The move came on...

Sanofi acquires Blueprint Medicines 2025 $9.5 billion, Sanofi Blueprint Medicines Ayvakit acquisition details, Sanofi buys US blood disorder drugmaker Blueprint Medicines price per share $129, impact of Sanofi acquisition on immunology pipeline, Blueprint Medicines avapritinib Ayvakit systemic mastocytosis expansion, biotech M&A rare disease strategy Sanofi Blueprint, commercialization and manufacturing plans after Sanofi acquisition of Blueprint, risks and milestones Sanofi Blueprint deal, what investors should know about Sanofi buying Blueprint Medicines.

Sanofi acquires Blueprint Medicines 2025 $9.5 billion, Sanofi Blueprint Medicines Ayvakit acquisition details, Sanofi buys US blood disorder drugmaker Blueprint Medicines price per share $129, impact of Sanofi acquisition on immunology pipeline, Blueprint Medicines avapritinib Ayvakit systemic mastocytosis expansion, biotech M&A rare disease strategy Sanofi Blueprint, commercialization and manufacturing plans after Sanofi acquisition of Blueprint, risks and milestones Sanofi Blueprint deal, what investors should know about Sanofi buying Blueprint Medicines.

Sanofi to Buy US Blood Disorder Drugmaker for Up to $9.5 Billion

French pharmaceutical giant Sanofi on June 2, 2025 announced an agreement to acquire Blueprint Medicines, a U.S.-based biopharma company...

Bristol Myers Squibb BioNTech $11.1 billion deal BNT327, BNT327 PD-L1 VEGF bispecific candidate Phase 3 lung cancer, how big pharma partners with biotech for oncology, implications of BMS BioNTech partnership for immuno-oncology, manufacturing and commercialization plans for bispecific antibodies, risks and milestones in large biotech licensing deals, what the BMS BioNTech deal means for Keytruda competitors, BioNTech oncology pivot validation deal analysis, how milestone-heavy pharma deals are structured and valued. Doctors In Business Journal

Bristol Myers Squibb BioNTech $11.1 billion deal BNT327, BNT327 PD-L1 VEGF bispecific candidate Phase 3 lung cancer, how big pharma partners with biotech for oncology, implications of BMS BioNTech partnership for immuno-oncology, manufacturing and commercialization plans for bispecific antibodies, risks and milestones in large biotech licensing deals, what the BMS BioNTech deal means for Keytruda competitors, BioNTech oncology pivot validation deal analysis, how milestone-heavy pharma deals are structured and valued. Doctors In Business Journal

Bristol Myers Squibb Signs $11 Billion Cancer Drug Deal with BioNTech: What It Means for the Pharma Landscape

Bristol Myers Squibb and BioNTech announced a landmark strategic partnership in mid-2025 to co-develop and co-commercialize a...

bottom of page